Biotherapy and Immunotherapy Treatments — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cancer immunotherapy — encompassing biotherapy and targeted biological agents — harnesses or augments the patient's own immune system to recognise and destroy cancer cells. Unlike conventional cytotoxic chemotherapy, which kills rapidly dividing cells indiscriminately, immunotherapy works by releasing immune brakes (checkpoint inhibitors), redirecting immune effectors directly to tumour antigens (CAR-T cells, bispecific antibodies), or actively vaccinating the immune system against tumour-specific mutations (cancer vaccines).

The modern immunotherapy era began with ipilimumab's FDA approval for metastatic melanoma in 2011, demonstrating for the first time that sustained long-term survival — including apparent cures — was achievable in a disease previously considered uniformly fatal at the metastatic stage. The subsequent approval of PD-1 inhibitors pembrolizumab and nivolumab across multiple tumour types transformed oncology practice through the 2010s and into the 2020s.

The field now encompasses several mechanistically distinct classes: immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, or CTLA-4; chimeric antigen receptor T-cell (CAR-T) therapies using genetically engineered autologous T cells; bispecific T-cell engager antibodies linking a tumour antigen to CD3 on T cells; therapeutic cancer vaccines including personalised neoantigen mRNA vaccines; and tumour-infiltrating lymphocyte (TIL) therapy, recently approved for melanoma. Together, these modalities have transformed the treatment landscape for more than 15 major cancer types.

Biomarker-driven patient selection is central to immunotherapy: PD-L1 expression (tumour proportion score — TPS for NSCLC; combined positive score — CPS for gastric/cervical/triple-negative breast cancer), tumour mutational burden (TMB ≥10 mutations per megabase), and mismatch repair deficiency/microsatellite instability-high (dMMR/MSI-H) status are established predictive biomarkers determining eligibility and likely response.

Immunotherapy is now approved or under active investigation across a wide spectrum of malignancies:

• Non-small cell lung cancer (NSCLC): Pembrolizumab (KEYNOTE-024: PD-L1 TPS ≥50%), nivolumab plus ipilimumab (CheckMate-227: TMB ≥10 mut/Mb), and atezolizumab (IMpower110) are first-line options. Durvalumab (PACIFIC trial) is standard consolidation after concurrent chemoradiation in unresectable Stage III NSCLC, improving 5-year overall survival to 42.9% versus 33.4% with placebo.
• Melanoma: Ipilimumab plus nivolumab (CheckMate-067) achieves 6.5-year overall survival of 57% in advanced melanoma. Adjuvant pembrolizumab or nivolumab improves relapse-free survival in resected Stage III–IV disease. Lifileucel (TIL therapy) is now approved for patients who have progressed on anti-PD-1 and BRAF-targeted therapy.
• Urothelial carcinoma: Pembrolizumab (KEYNOTE-045), atezolizumab, and avelumab (maintenance after platinum-based chemotherapy — JAVELIN Bladder 100 trial) are approved. Erdafitinib plus cetrelimab is under evaluation for FGFR-altered disease.
• Head and neck squamous cell carcinoma (HNSCC): Pembrolizumab is approved first-line as monotherapy (CPS ≥1) and in combination with platinum/5-FU (KEYNOTE-048), replacing cetuximab-platinum as standard of care.
• Triple-negative breast cancer (TNBC): Pembrolizumab plus chemotherapy (KEYNOTE-522) improves pathological complete response and event-free survival in early-stage TNBC, with atezolizumab plus nab-paclitaxel also approved for PD-L1 CPS ≥10 metastatic TNBC.
• MSI-H/dMMR pan-tumour approval: Pembrolizumab received tumour-agnostic FDA approval for MSI-H or dMMR solid tumours (KEYNOTE-158), marking the first biomarker-defined cancer approval irrespective of tumour histology.
• Haematological malignancies (CAR-T): CD19-directed CAR-T cells (axicabtagene ciloleucel, tisagenlecleucel) are approved for relapsed/refractory large B-cell lymphoma and paediatric/young adult B-ALL. BCMA-directed CAR-T cells (ciltacabtagene autoleucel, idecabtagene vicleucel) and lisocabtagene maraleucel are approved for relapsed/refractory multiple myeloma. Blinatumomab (bispecific CD19xCD3) is approved for ALL and minimal residual disease clearance.
• Prostate cancer: Sipuleucel-T, the first FDA-approved cancer vaccine, targets prostatic acid phosphatase (PAP) fused to GM-CSF; the IMPACT trial demonstrated a 4.1-month overall survival benefit in asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.

Patient selection for immunotherapy is guided by tumour biomarkers, performance status, and organ function:

• PD-L1 expression: PD-L1 immunohistochemistry using validated assays (22C3 pharmDx for pembrolizumab, 28-8 for nivolumab, SP142/SP263 for atezolizumab/durvalumab) is mandatory before first-line checkpoint inhibitor therapy in NSCLC, HNSCC, gastric/GEJ cancer, and urothelial carcinoma. The threshold varies by tumour type: TPS ≥50% for pembrolizumab monotherapy in NSCLC; CPS ≥10 for TNBC; CPS ≥1 for HNSCC.
• TMB (tumour mutational burden): TMB ≥10 mutations per megabase (mut/Mb) by comprehensive genomic profiling (e.g., FoundationOne CDx) is an FDA-approved companion diagnostic for pembrolizumab (KEYNOTE-158) across solid tumours and for nivolumab plus ipilimumab in NSCLC (CheckMate-227).
• MSI-H/dMMR status: Universal testing for mismatch repair protein expression (MLH1, MSH2, MSH6, PMS2) by IHC or MSI-PCR/NGS is recommended for colorectal, endometrial, and gastric cancers, and is increasingly tested pan-tumour. dMMR/MSI-H patients have the highest response rates to PD-1 blockade (response rates 40–60% in multiple tumour types).
• Performance status: Most clinical trials enrolled patients with ECOG performance status 0–1. Patients with ECOG PS 2 or higher may derive benefit but face higher rates of treatment discontinuation due to toxicity. Autoimmune co-morbidities (active inflammatory bowel disease, interstitial lung disease) are relative contraindications to checkpoint inhibitors.
• CAR-T eligibility: Requires adequate organ function, ECOG PS 0–2, confirmed CD19 or BCMA expression on tumour cells, absence of active CNS disease (for most products), ability to undergo leukapheresis, and a 3–4 week manufacturing window. Prior anti-CD19 therapy is a contraindication for some CD19-directed products.
• Organ function requirements: Standard ICI eligibility requires adequate hepatic (bilirubin ≤1.5× ULN, AST/ALT ≤2.5× ULN), renal (creatinine clearance ≥30–60 mL/min by product), and pulmonary function. Active systemic corticosteroid use (>10 mg/day prednisone equivalent) may attenuate ICI efficacy and is a relative contraindication.

Modern cancer immunotherapy encompasses five mechanistically distinct categories:

• Immune checkpoint inhibitors (ICI): These monoclonal antibodies block inhibitory receptors that suppress T-cell activity. PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab) block the PD-1 receptor on T cells, preventing ligand-induced T-cell exhaustion. PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) block PD-L1 on tumour or immune cells. CTLA-4 inhibitors (ipilimumab, tremelimumab) prevent CTLA-4-mediated downregulation of T-cell priming in lymph nodes. Combination ICI (ipilimumab + nivolumab) achieves higher response rates but increased toxicity; the HIMALAYA trial validated tremelimumab-PACE plus durvalumab (STRIDE regimen) in hepatocellular carcinoma.
• CAR-T cell therapy: Autologous T cells are collected by leukapheresis, genetically engineered ex vivo to express a chimeric antigen receptor (CAR) targeting a tumour surface antigen, expanded to billions of cells, and reinfused after lymphodepletion chemotherapy (fludarabine + cyclophosphamide). Approved products include axicabtagene ciloleucel (Yescarta; CD19; DLBCL/follicular lymphoma), tisagenlecleucel (Kymriah; CD19; paediatric ALL, DLBCL), ciltacabtagene autoleucel (Carvykti; BCMA; multiple myeloma — CARTITUDE-1: 98% response rate), and lisocabtagene maraleucel (Breyanzi; CD19; DLBCL). Manufacturing typically takes 3–4 weeks; vein-to-vein time is a critical logistical challenge for rapidly progressive disease.
• Bispecific antibodies: Bispecific T-cell engagers link two antigen-binding domains — one targeting a tumour antigen and one engaging CD3 on T cells — to redirect polyclonal T cells against tumour cells. Blinatumomab (CD19xCD3; ALL, MRD clearance) is the prototype. Newer agents include teclistamab (BCMAxCD3; multiple myeloma), epcoritamab (CD20xCD3; DLBCL), and mosunetuzumab (CD20xCD3; follicular lymphoma).
• Cancer vaccines: Sipuleucel-T (Provenge) is an autologous dendritic cell vaccine targeting PAP-GM-CSF fusion protein, approved for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. Personalised neoantigen mRNA vaccine mRNA-4157 (V940, in combination with pembrolizumab) demonstrated a 44% reduction in risk of recurrence or death versus pembrolizumab alone in resected high-risk melanoma (KEYNOTE-942 trial), representing a breakthrough in personalised oncology.
• Tumour-infiltrating lymphocyte (TIL) therapy: Lifileucel (Amtagvi), FDA-approved February 2024, is produced by harvesting TILs from a surgically resected tumour fragment, expanding them ex vivo to 5–150 billion cells, and reinfusing after lymphodepletion. It is approved for unresectable or metastatic melanoma after failure of anti-PD-1 and BRAF-targeted therapy (C-144-01 trial: 31.5% objective response rate).

Immunotherapy offers advantages over conventional cytotoxic therapies that have fundamentally changed oncology practice:

• Durable long-term responses and potential cure: A proportion of patients treated with checkpoint inhibitors achieve durable complete responses that persist years after treatment discontinuation — a phenomenon rarely seen with chemotherapy. In the CheckMate-067 trial (ipilimumab + nivolumab for advanced melanoma), 57% of patients were alive at 6.5 years, with the survival curve appearing to plateau, suggesting a "cured fraction."
• Tumour-agnostic efficacy: The MSI-H/dMMR pan-tumour approval of pembrolizumab established that certain biomarker profiles predict immunotherapy response regardless of the tissue of origin — enabling treatment of rare tumour types that previously had no standard targeted therapy.
• Meaningful responses in previously refractory disease: CAR-T cell therapies achieve response rates of 60–98% in heavily pre-treated haematological malignancies where all other options have failed, with complete responses in 40–60% of patients with relapsed/refractory DLBCL after two or more lines of therapy.
• Improved quality of life vs. chemotherapy: In NSCLC patients with PD-L1 TPS ≥50%, pembrolizumab monotherapy (KEYNOTE-024) achieved superior progression-free survival and overall survival versus platinum-based chemotherapy with a markedly more favourable toxicity profile, including less haematological toxicity, alopecia, and nausea.
• Synergy with other modalities: Immunotherapy combines effectively with chemotherapy (chemo-IO), radiotherapy (abscopal effect), targeted therapy, and surgery. Neoadjuvant pembrolizumab plus chemotherapy (KEYNOTE-522) has become standard-of-care in early TNBC, improving pCR rates by approximately 13 percentage points.
• Personalised medicine paradigm: Personalised neoantigen vaccines (mRNA-4157) represent the leading edge of truly individualised cancer therapy, synthesised based on each patient's unique mutational landscape within approximately 6–8 weeks of tumour sequencing.

Immunotherapy has a distinct toxicity profile driven by non-specific immune activation, fundamentally different from chemotherapy toxicity. Immune-related adverse events (irAEs) can affect virtually any organ system:

• Colitis (enterocolitis): The most common serious irAE with CTLA-4 inhibitors (ipilimumab: ~30% any grade; ~12% Grade 3–4). Presents as diarrhoea ± bloody stool, abdominal cramping, and fever. Management: Grade 1 — supportive care, hold ICI; Grade 2 — prednisone 1 mg/kg/day; Grade 3–4 — methylprednisolone 1–2 mg/kg IV, and if no improvement within 2–3 days, infliximab 5 mg/kg IV (first-line) or vedolizumab. ICI is permanently discontinued after Grade 4 colitis.
• Immune-mediated pneumonitis: Occurs in approximately 5% of patients on PD-1/PD-L1 inhibitors (higher with combination ICI or concurrent thoracic radiotherapy). Presents with dyspnoea, cough, and CT ground-glass opacities. Grade 2: hold ICI, prednisone 1–2 mg/kg/day with slow taper over ≥4 weeks. Grade 3–4: methylprednisolone 1–2 mg/kg IV, add infliximab or mycophenolate if no improvement, permanently discontinue ICI.
• Immune-mediated myocarditis: Rare but potentially fatal irAE occurring in less than 1% of patients receiving ICI, but with a case fatality rate of 25–50% for fulminant presentations. Presents with chest pain, dyspnoea, elevated troponin, and cardiac arrhythmias. Requires immediate high-dose corticosteroids (methylprednisolone 1 g/day IV), discontinuation of ICI, and cardiology/CCU care. Troponin monitoring at baseline and during the first 3 months is recommended by some guidelines.
• Endocrinopathies: Thyroid dysfunction (hypothyroidism, hyperthyroidism, thyroiditis) occurs in approximately 10–15% of patients on PD-1 inhibitors; managed with levothyroxine or temporary antithyroids. Hypophysitis (pituitary inflammation) is more common with ipilimumab (5–10%), presenting with headache, fatigue, hyponatraemia, and hypopituitarism; managed with physiological hydrocortisone replacement (not typically reversal with steroids). Primary adrenal insufficiency requires lifelong mineralocorticoid and glucocorticoid replacement.
• Cytokine release syndrome (CRS) with CAR-T: CRS occurs in 70–90% of patients post-CAR-T infusion, typically within 1–14 days. Graded I–IV (ASTCT criteria); Grade 1–2 managed with antipyretics and, if needed, tocilizumab 8 mg/kg IV. Grade 3–4 (hypotension, hypoxia) requires tocilizumab plus dexamethasone 10 mg IV. Grade 4 CRS requires ICU-level management.
• Immune effector cell-associated neurotoxicity syndrome (ICANS): Occurs in 20–60% of CAR-T recipients (more frequent with CD19-directed products), presenting with encephalopathy, aphasia, tremor, and, rarely, cerebral oedema. Managed with dexamethasone 10 mg IV every 6 hours; Grade 4 ICANS requires high-dose methylprednisolone and ICU care.
• Other significant irAEs: Hepatitis (Grade 3–4: prednisone ± mycophenolate), nephritis, dermatitis (including Stevens-Johnson syndrome), uveitis, and neurological irAEs (Guillain-Barré, myasthenia gravis) are reported. Baseline autoimmune conditions require specialist assessment before initiating ICI.

Structured monitoring and response assessment protocols are essential throughout and after immunotherapy:

• Response assessment imaging: CT of chest/abdomen/pelvis using iRECIST or RECIST 1.1 criteria is performed every 8–12 weeks during ICI treatment. Pseudoprogression (initial tumour enlargement due to immune infiltration before response) occurs in approximately 3–5% of cases; confirmatory imaging at 4–6 weeks before declaring progression is recommended to avoid premature ICI discontinuation.
• Baseline and on-treatment irAE monitoring: Before each ICI cycle: liver function tests, thyroid function (TSH), serum creatinine, and complete blood count. Echocardiography and troponin monitoring at baseline are increasingly advocated in high-risk populations (prior cardiac disease, combination ICI). Patient education regarding irAE symptoms (diarrhoea, shortness of breath, skin rash, visual changes) is mandatory, as early recognition significantly reduces irAE severity.
• Duration of immunotherapy: Standard duration for most approved checkpoint inhibitor regimens is 2 years (35 cycles of pembrolizumab at 3-weekly intervals). For patients who achieve complete response, discontinuation after 1 year may be appropriate per ESMO guidelines. Maintenance avelumab in urothelial carcinoma continues until disease progression or unacceptable toxicity.
• Post-CAR-T monitoring: Following CAR-T infusion, patients require daily assessment for CRS/ICANS for at least 7 days (inpatient for most products for 7–14 days). Long-term monitoring includes B-cell aplasia management (monthly IVIG for hypogammaglobulinaemia), chimerism/persistence of CAR-T cells, and infectious prophylaxis (PCP, viral). Day 28 bone marrow assessment with MRD testing is standard for ALL CAR-T patients.
• Endocrine follow-up: Endocrinopathies arising from ICI are usually permanent and require lifelong hormonal replacement. Endocrinology co-management is recommended for patients with hypophysitis, primary adrenal insufficiency, or Type 1 diabetes mellitus precipitated by ICI.
• Long-term survivorship: Patients achieving durable complete response on ICI require surveillance imaging (typically CT q3–6 months for 2 years post-discontinuation, then annually) and monitoring for late-emerging irAEs, which can occur months to years after the last ICI dose.

Immunotherapy agents are among the most expensive oncological treatments globally, creating significant access disparities:

• Checkpoint inhibitor costs: In the United States, annual pembrolizumab therapy costs approximately USD 150,000–180,000 per year at list price. Nivolumab and atezolizumab are similarly priced. In the UK, ICIs are available through NICE Technology Appraisal and NHS England Cancer Drugs Fund, which negotiates confidential rebated pricing. In India, biosimilar PD-1 inhibitors (e.g., pembrolizumab biosimilars) are increasingly available at approximately 30–40% of originator cost.
• CAR-T cell therapy costs: CAR-T cell products are among the most expensive medical interventions globally — axicabtagene ciloleucel (Yescarta) has a US list price of approximately USD 373,000 per infusion; tisagenlecleucel (Kymriah) approximately USD 475,000 for paediatric ALL. These costs do not include hospitalisation, bridging therapy, management of CRS/ICANS, or long-term follow-up. NHS England funds CAR-T through individual funding requests and commercial access agreements.
• Biomarker testing costs: Comprehensive genomic profiling for TMB, MSI status, and multiple actionable alterations (FoundationOne CDx, MSK-IMPACT) costs USD 3,000–5,000 in the US but is covered by Medicare for eligible patients. IHC-based PD-L1 testing and MSI-PCR are widely available in most oncology centres globally at low cost.
• Manufacturing timeline (CAR-T): The 3–4 week manufacturing window for autologous CAR-T products introduces indirect costs through bridging chemotherapy, disease monitoring, and potentially disease progression during manufacturing — a particular concern for rapidly progressive lymphomas.
• Medical tourism for immunotherapy: Some patients travel to India, Thailand, or South Korea for access to immunotherapy drugs at lower cost (20–40% of US pricing in some centres) or for CAR-T programmes at specialised academic centres. JCI-accredited oncology centres in these countries use the same FDA/EMA-approved agents and follow international oncology protocols. Patients should verify drug provenance and institutional experience before travelling.
• Government and access programmes: Many pharmaceutical manufacturers offer patient assistance programmes. In Europe, EMA approval generally enables national health authority access. In India, the PM-JAY (Ayushman Bharat) scheme has limited cancer drug coverage; state cancer funds supplement access in some regions.

Immunotherapy is often used in combination with or as an alternative to the following modalities, depending on cancer type, biomarker status, and disease stage:

• Targeted therapy: For cancers with actionable driver mutations (EGFR/ALK/ROS1 in NSCLC, BRAF V600E in melanoma, HER2 in breast/gastric cancer, BRCA in breast/ovarian), targeted tyrosine kinase inhibitors or antibody-drug conjugates typically produce faster responses and superior outcomes compared with immunotherapy in the biomarker-selected population. The optimal sequencing of targeted therapy and immunotherapy is an area of active investigation.
• Cytotoxic chemotherapy: Remains the backbone of treatment in tumour types with low immunogenicity (pancreatic cancer, microsatellite-stable colorectal cancer) and in combination with ICI to enhance tumour antigen presentation and neoantigen release. Platinum doublets combined with pembrolizumab are standard first-line therapy in PD-L1 negative or low-expressing NSCLC.
• Radiotherapy: External beam radiotherapy induces immunogenic cell death and can enhance systemic immune responses (abscopal effect), potentially synergising with concurrent or sequential ICI. The PACIFIC regimen (durvalumab after CRT in Stage III NSCLC) exemplifies this combination. Stereotactic radiosurgery is used for local control of oligometastatic disease in ICI-responsive tumours.
• Antibody-drug conjugates (ADC): ADCs (trastuzumab deruxtecan, enfortumab vedotin, sacituzumab govitecan) deliver cytotoxic payloads directly to antigen-expressing tumour cells with less systemic toxicity than conventional chemotherapy. They are increasingly combined with ICI in clinical trials.
• Allogeneic haematopoietic stem cell transplantation (alloHSCT): For haematological malignancies, alloHSCT remains an option alongside or after CAR-T therapy. The graft-versus-tumour (GvT) effect provides immunological disease control distinct from CAR-T. The choice between CAR-T and alloHSCT depends on donor availability, patient fitness, disease characteristics, and centre expertise.
• Best supportive care / clinical trials: For patients who are not candidates for immunotherapy due to performance status, organ dysfunction, or lack of biomarker eligibility, best supportive care or enrolment in clinical trials of next-generation immunotherapy agents (next-generation CAR-T constructs, LAG-3 inhibitors, TIGIT inhibitors, bispecific antibodies in development) should be considered at specialist centres.